weight loss drug prescriptions semaglutide tirzepatide q3 2024 GLP-1 prescription trends through June Weight-loss drug powers Lilly results,

If you have been on a stable dose for 8 or more weeks with no change, discuss a dose increase with your provider

(2025) The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis

When a medication is in shortage, meaning that the commercially available versions cannot meet patient demand, compounding pharmacies are granted temporary authority to prepare alternative versions to help fill the gap

Retatrutide Retatrutide is a new weight loss treatment, manufactured by Eli Lilly, to treat obesity and type 2 diabetes

If you decide (or are advised) to go down the medical route, there are also some oestrogen creams and treatments and over-the-counter treatments

In the SURPASS program, gastrointestinal side effects associated with the use of tirzepatide were similar to those observed with semaglutide and GLP1-RA drugs in general, both in terms of frequency and duration [3]